surmount 3 tirzepatide trials after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase trial Eli Lilly's tirzepatide scores again, – Tirzepatide after intensive lifestyle intervention

Supply : In 2025, supply bottlenecks will continue to ease following extensive efforts by Novo Nordisk and Lilly to step up manufacturing, with important implications for competitive dynamics: The large-scale opportunity for compounders will be closing

Equally important is a robust help center where common questions are answered plainly and quickly

It usually means gradual dose escalation, side-effect review, hydration and bowel-function check-ins, weight tracking, refill planning, and clear guidance on when the dose should hold, continue, or change

[ CrossRef ] [ Google scholar ] [ PubMed ] Pickart L, Margolina A

On the other hand, semaglutide is a GLP-1 receptor agonist, primarily targeting the GLP-1 receptor

Both are prescription-only and eligible for FSA reimbursement if medically necessary